(19)
(11) EP 2 768 308 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.08.2018 Bulletin 2018/31

(45) Mention of the grant of the patent:
18.04.2018 Bulletin 2018/16

(21) Application number: 12840771.5

(22) Date of filing: 12.10.2012
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
C07F 9/6561(2006.01)
A61P 35/00(2006.01)
C07H 15/26(2006.01)
A61K 31/47(2006.01)
(86) International application number:
PCT/US2012/059988
(87) International publication number:
WO 2013/056073 (18.04.2013 Gazette 2013/16)

(54)

COMPOUNDS AND ANTI-TUMOR NQO1 SUBSTRATES

VERBINDUNGEN UND ANTI-TUMOR-NQO1-SUBSTRATE

COMPOSÉS ET SUBSTRATS ANTITUMORAUX NQO1


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 14.10.2011 US 201161547166 P
20.06.2012 US 201261662163 P

(43) Date of publication of application:
27.08.2014 Bulletin 2014/35

(73) Proprietors:
  • The Board of Trustees of the University of Illinois
    Urbana, IL 61801 (US)
  • The Board of Regents of The University of Texas System
    Austin, TX 78701 (US)

(72) Inventors:
  • HERGENROTHER, Paul J.
    Champaign, Illinois 61822 (US)
  • BOOTHMAN, David A.
    Dallas, Texas 75230 (US)
  • BAIR, Joseph S.
    Albany, California 94706 (US)
  • PALCHAUDHURI, Rahul
    Cambridge , Massachusetts 02139 (US)
  • PARKINSON, Elisabeth I.
    Champaign, Illinois 61820 (US)

(74) Representative: FRKelly 
27 Clyde Road
Dublin D04 F838
Dublin D04 F838 (IE)


(56) References cited: : 
WO-A2-2012/085532
US-A- 5 716 963
US-A- 4 906 562
   
  • PEREZ J M ET AL: "Concise Preparation of 1,8-Diazaanthracene-2,7,9,10-Tetraones. Two Alternative Syntheses of the Natural Antifolate Diazaquinomycin A", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 56, no. 26, 1 June 2000 (2000-06-01), pages 4575-4583, XP004202151, ISSN: 0040-4020, DOI: 10.1016/S0040-4020(00)00371-9
  • JOSEPH S. BAIR ET AL: "Chemistry and Biology of Deoxynyboquinone, a Potent Inducer of Cancer Cell Death", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 132, no. 15, 21 April 2010 (2010-04-21), pages 5469-5478, XP055187222, ISSN: 0002-7863, DOI: 10.1021/ja100610m
  • X. HUANG ET AL: "An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis", CANCER RESEARCH, vol. 72, no. 12, 15 June 2012 (2012-06-15) , pages 3038-3047, XP055187225, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-11-3135
  • DIAZ-GUERRA LUIS M ET AL: "Half-wave potentials of 1-aza and 1,8-diazaanthraquinones", CAPLUS,, 1 January 1995 (1995-01-01), XP002480321,
  • LI ET AL.: 'Modulating Endogenous NQ01 Levels Identifies Key Regulatory Mechanisms of Action of b-Lapachone for Pancreatic Cancer Therapy' CLIN CANCER RES vol. 17, no. 2, 15 January 2011, pages 275 - 285, XP055096513
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).